Novo Nordisk's new CEO is set to face intense investor scrutiny this week as the Wegovy-maker shakes up its board and pursues ...
But Doustdar also seems to recognize what he has in Novo Nordisk, the 100-year-old pharma that brought insulin to the masses, ...
The Wegovy-maker will release its third-quarter results on Wednesday, Doustdar’s first since taking charge in August with the ...
Pharmaceutical Technology on MSN
Pfizer clinches $10bn Metsera deal as Novo Nordisk retreats
One of the most compelling acquisition sagas in the pharma industry in recent times has come to an end, with Pfizer prevailing over Novo Nordisk in a fierce bidding war to acquire ...
Stocktwits on MSN
Novo Nordisk Q3 Preview: Analysts See Profit Drop As Obesity Market Cools, Pfizer Tensions Rise
Analysts expect Novo Nordisk’s Q3 revenue to fall 2% to $11.87 billion and earnings per share to drop as competition from Eli ...
3don MSN
Pfizer clinches deal for obesity drug developer Metsea after a bidding war with Novo Nordisk
Pfizer has signed a deal to purchase Metsera Inc., an obesity drugmaker in the development stage, after winning a bidding war against Novo Nordisk. Metsera, based in New York, is developing oral ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback